[Translation] Phase III clinical study of AL8326 tablets for the treatment of patients with small cell lung cancer whose disease has progressed or relapsed after receiving at least second-line treatment regimens
study
主要目的
评价AL8326片单药治疗二线及以上系统性方案治疗后复发或进展的小细胞肺癌患者的总生存期(OS)疗效。
次要目的
评价AL8326片单药在二线及以上系统性方案治疗后复发或进展的小细胞肺癌患者中的无进展生存期(PFS)和其他有效性指标.
[Translation] main purpose
To evaluate the overall survival (OS) efficacy of AL8326 tablets as a single drug in the treatment of small cell lung cancer patients who relapse or progress after second-line or above systemic regimens.
secondary purpose
To evaluate the progression-free survival (PFS) and other effectiveness indicators of AL8326 tablets as a single drug in patients with small cell lung cancer that relapses or progresses after second-line or above systemic regimen treatment.